Theranica’s Post

ECMO for Premature Neonates- Are we there yet? This study questions the long-established contraindications of GA <34 weeks and BW of 2.0 kg in the neonatal population. Comparing outcome between prematurely born before, or at 34 GA, the most recently published study from the ELSO Registry showed a survival of 48% in babies born GA 29-33 compared to 58% for those born at GA 34. The risk of ICH was similar before or after week 34, 21% vs. 17%, respectively. Survival rates for birth weight <2.0 kg were 53%, compared to 77% survival, for BW ≥2.0 kg in one study44. In a study by Wong and colleagues, the lowest weight for which a survival rate of >40% could be achieved was 1.6 kg. There was an increased risk of major ICH in BW 2-2.5 kg compared to >2.5 kg (28% vs.11%, respectively). The authors suggest that Prem-ECMO (GA 32-33) could be considered when restricted to experienced high-volume neonatal ECMO centers, with closed monitoring and rigorous reporting to the ELSO registry, providing close targeting of oxygen delivery for prevention of retinopathy and being active participants in continuous development of technology and devices for improved biocompatibility for use in the neonate. https://lnkd.in/eHhEMtk7

A late-breaking abstract presented at the American Heart Association Scientific Sessions demonstrated real-world clinical efficacy of our AI-enabled technology to detect cardiac dysfunction during and soon after pregnancy. 📈 The results showed that screening using an Eko digital stethoscope paired with the company’s reduced left ventricular ejection fraction (HFrEF) algorithm identified twice as many cases of pregnancy-related cardiomyopathy among women in Nigeria compared to standard clinical care. 💡 According to the AHA, Peripartum cardiomyopathy is a type of heart failure that can affect women late in pregnancy or after pregnancy. The disease weakens the heart, resulting in a decrease in the amount of blood that is pumped from the heart to other parts of the body. It is typically diagnosed towards the end of pregnancy or in the months following and may be difficult for health professionals to detect because many of the symptoms are similar to those seen with normal pregnancy, such as shortness of breath and swelling in the feet and legs. 🎙️ Dr. Demilade Adedinsewo, Primary Investigator and Cardiologist at Mayo Clinic commented, “We demonstrated for the first time in an obstetric population that AI-guided screening using a digital stethoscope improved the diagnosis of this potentially life-threatening and treatable condition. This research can change current clinical practice from one that is reactive and symptom-driven to a more proactive approach of identifying pregnancy-related cardiac dysfunction using a simple, low-cost, and effective screening tool. Earlier diagnosis would facilitate prompt and appropriate management of cardiomyopathy and reduce associated disease and death.” 🔗 Explore the published findings in a news release from the American Heart Association: https://lnkd.in/grtcZTR7 Eko’s AI-enabled technology is commercially available in the U.S. and marketed to health systems as SENSORA™. The company’s algorithm for HFrEF detection is undergoing U.S. FDA review for 510(k) clearance with the intent to market under SENSORA™ once 510(k) is obtained. U.S.-based health systems interested in learning more about SENSORA™ can visit ekosensora.com. #ekohealth #ekosensora #aha23 #CardiacCare #AI #DigitalHealth #Innovation #HeartDisease #HealthTech #aiinhealthcare

🔍 **Ensuring Fetal Health: The Importance of Rechecking Cord Insertion for a Three-Vessel Cord** 🔍 In the detailed landscape of prenatal care, the significance of rechecking fetal cord insertion for a three-vessel cord often goes underrecognized. Thrombosis of umbilical cord vessels, albeit rare (with an incidence of about 0.08% in pregnancies), poses potential risks that warrant a meticulous approach. Venous thromboses are more common than arterial ones, yet the implications of an umbilical artery thrombosis, despite its rarity (0.0025% to 0.045% incidence), could be profound. Factors like anatomical cord dysplasia, abnormal cord length, or atypical Wharton jelly morphology might predispose to these occlusions. Maternal conditions, including pregestational diabetes, hypertensive disorders, and thrombophilia, alongside lifestyle factors like smoking, further accentuate the risk. The critical nature of detecting umbilical artery thrombosis, which could lead to severe outcomes such as intrauterine growth restrictions, fetal distress, or even cerebral palsy, underscores the necessity for precise prenatal screenings. Ultrasound serves as our primary tool in detecting these anomalies. Yet, accurate diagnosis demands experienced clinicians who can differentiate between thrombosis and a genuine single umbilical artery. Given the severe repercussions of umbilical artery thrombosis, strategies such as planned elective deliveries with corticosteroid therapy for lung maturation could be considered. Each case calls for personalized management, emphasizing the need for a thorough and informed approach. 🤓 I witnessed a case of Umbilical artery thrombosis in correlation with intrauterine growth restriction, I never knew such a thing could even happen! Let's prioritize comprehensive evaluations to ensure healthier outcomes for our future generations. #PrenatalCare #FetalHealth #MedicalUltrasound #ClinicalExcellence

MedTech plays a vital role in Newborn Screening by harnessing advanced diagnostic tools. The cutting-edge technologies help identify metabolic, genetic, and congenital disorders with remarkable precision. By analyzing a small blood sample from a newborn's heel prick, we can identify rare and potentially life-threatening conditions swiftly, paving the way for healthier, happier beginnings. In my latest article on New18, you can gain a further understanding of the capabilities and applications of MedTech and Newborn Screening in the early detection of health issues in infants. https://lnkd.in/dX6X9ZV2 #NewbornHealth #EarlyDetection #NewbornScreening #MedTech Trivitron Healthcare News18 India

Having a blood sample drawn can be unpleasant, a hassle and downright terrifying for those who fear needles. Meanwhile, everyone who menstruates collects blood every month. California-based startup Qvin is tapping into that natural process with Q-Pad, a menstrual pad that functions as a medical testing device and has just been cleared by the FDA. Q-Pad is an organic cotton pad holding a removable strip. Once enough blood has been collected in the pad, the user takes out the strip and sends it to a certified laboratory for clinical testing. Results are provided through Qvin's app. The current FDA clearance is for an A1c test kit that measures a person's average blood sugar over three months — a key health indicator for pre-diabetes and diabetes. Other tests are in the works: Dr. Paul Blumenthal, Professor Emeritus of Obstetrics and Gynecology at Stanford University, says: "For instance, women seeking to understand their fertility status can soon monitor various reproductive hormones via menstrual blood using the Q-Pad. In addition, published research indicates that the Q-Pad could be a convenient, user-friendly, and efficient way of screening for the Human Papilloma Virus (HPV) as part of global cervical cancer prevention efforts." Early-access priced at USD 39, Q-Pad is available for preordering now, with shipping to follow early 2024. Read our Trend Bite for this innovation 👉 https://hubs.la/Q02f-SFn0 #femtech #telehealth #innovation #trendwatching

CardioConcepts: Bromocriptine and the Future of Peripartum Cardiomyopathy Management Part I: What is Peripartum Cardiomyopathy? Peripartum cardiomyopathy (PPCM) is a  - non-ischemic cardiomyopathy  - systolic heart failure presenting in the last month of pregnancy or up to 5 - 6 months postpartum. - a diagnosis of exclusion and it’s symptoms may mimic the physiological changes asssociated with normal pregnancy in the peripartum period. Unlike women with pre-exisitng cardiac disease who develop symptomatic HF during the second trimester, women with PPCM develop symptomatic HF either during late pregnancy or in the early post-partum period. Studies show several risk factors associated with PPCM: - Pre-eclampsia (associated with subclinical LV dysfunction) - Hypertension - African descent - Multiple gestations (7%-14.5% in U.S.) - Advanced maternal age (>30) - A family hitory of cardiomyopathy suggests a genetic component Part Ib: Diagnostic criteria 1. LV EF < 45%, FS < 30% with or without LV dilatation 2. Occuring within the last month of pregnancy or up to 5 months in the postpartum period 3. All other causes of HF ruled out Remember! There must be no pre-existing structural heart disease #cardiology #cardiovascularhealth This is the first part of my new series CardioConcepts, check it out in my previous post! (Click the link below) 👇 https://lnkd.in/eew8xnaa

Physicians need to be well-educated about hormones for several reasons: 1. Understanding Normal Functioning: #Hormones play a crucial role in regulating various physiological processes in the body. A deep understanding of normal hormonal functioning is essential for physicians to identify abnormalities and deviations from the norm. 2. Diagnosing Hormonal Disorders: Many medical conditions are related to hormonal imbalances, such as thyroid disorders, diabetes, and hormonal cancers. Physicians need to be well-versed in hormone-related diagnostics to accurately identify and treat these conditions. 3. Effective Treatment Plans: Hormones are often involved in the regulation of metabolism, growth, immune function, and more. A comprehensive knowledge of hormones enables physicians to design effective treatment plans that target the underlying hormonal issues, leading to better patient outcomes. 4. Managing Endocrine Disorders: Endocrine disorders involve disruptions in the hormone-secreting glands. Physicians need to be knowledgeable about the endocrine system to diagnose and manage disorders like adrenal insufficiency, hypothyroidism, and others. 5. Reproductive Health: Hormones play a pivotal role in reproductive health. Physicians, especially those specializing in obstetrics and gynecology, should have a profound understanding of hormonal changes during pregnancy, menstrual cycles, and menopause to provide optimal care to their patients. 6. Individualized Patient Care: Every patient is unique, and hormonal imbalances can manifest differently in each individual. Physicians need to be educated about the complexities of hormones to tailor treatment plans that address the specific needs and conditions of each patient. 7. Preventing Complications: Hormonal imbalances, if left untreated, can lead to severe complications. Physicians must be able to recognize early signs of hormonal disorders and intervene promptly to prevent the progression of the condition and associated complications. In summary, a thorough knowledge of hormones is essential for physicians to diagnose, treat, and manage a wide range of medical conditions. It allows them to provide personalized and effective care, ultimately improving the overall health and well-being of their patients. #WhyPhysiciansNeedToUnderstandHormones #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences

I am delighted to share our publication of the consensus update from the Demyelinating Diseases Group of  Sociedad Española de Neurología on the treatment and management of #multiplesclerosis. This document reflects an era of significant changes in #multiplesclerosis treatment, ranging from the introduction of new drugs to the reevaluation of treatment strategies in special situations like pregnancy and vaccination. 🔍 Key Updates include: - The integration of high-efficacy disease-modifying treatments (DMTs) at early stages of MS. - A patient-centered approach to treatment, considering the patient's perspective in clinical decision-making. - The move away from the terminology "treatment lines" in favour of a more personalized approach based on efficacy. - The adoption of new technologies for remote monitoring to improve patients' quality of life. - Updated recommendations for special situations like pregnancy and vaccination.   This document shows our commitment to improving the lives of those affected by #multiplesclerosis, providing healthcare professionals with the latest insights and guidelines for optimal patient care. 🔗 english https://lnkd.in/dwpRJuER 🔗 spanish  https://lnkd.in/dkqu39_p A huge thank you to all the experts whose contributions made this groundbreaking work possible!! Ester Moral , Sara Eichau , Dr. Rafael Arroyo González , Dr. José Meca Lallana , María Otano Martínez , Luis Brieva Ruiz Lucienne Costa-Frossard França , Montserrat Gonzalez Platas , Adrián Arés Luque , Jordi Rio #MultipleSclerosis #Neurology #MSTreatment #PatientCare #MSResearch Asociación Española de Esclerosis Múltiple (AEDEM-COCEMFE) Esclerosis Múltiple España FEMM.- Fundación Esclerosis Múltiple de Madrid  

A new research has been published ✅ Abstract: "The aim of the study was to examine the association between sonographic estimated fetal weight and obstetrical and neonatal outcomes in women delivering macrosomic newborns, with a particular focus on understanding how antenatal suspicion of impending macrosomia influences obstetrical management decisions. Findings revealed that women with estimated fetal weight ≥3800 grams had a higher cesarean delivery rate and lower operative delivery rate compared to those with EFW <3800 grams. Primiparity, diabetes mellitus, and maternal obesity were identified as independent predictors of cesarean delivery in pregnancies with larger estimated fetal weight. Despite the higher cesarean delivery rate associated with larger estimated fetal weight, no improvement in maternal and neonatal outcomes was observed. The study's outcomes underscore the pivotal role of fetal weight estimation in shaping obstetrical management decisions, urging a critical review of its influence on clinical practices to enhance maternal and neonatal outcomes while minimizing unnecessary interventions". https://lnkd.in/dy9U4Pvy inshirah sgayer shannan Lior Lowenstein Raneen Abu Shqara

Femtech Insider Functional TransGenomics #genome2life Health in Her HUE secures $3M in seed funding to expand services for women of color. Heranova Lifesciences raises $13.5M for novel non-invasice diagnostics and treatment of endometriosis and bacterial vaginosis. Annabella Tech secures $8.5M seed funding to introduce its breast pump tech into the U.S. market. @Hera Biotech is to acquire endometriosis diagnostic assets from Scailyte in a move towards non surgical diagnosis. Cosette acquires HSDD treatment Vyleesi from Palatin for $12M amid market challenges. Dr. Reddy's acquires menopause supplement brand MenoLabs from Amyris in Chapter 11 auction. Qvins - Qvinnor inom Insurance Q-Pad makes history with first FDA approval for menstrual blood health testing. Owlet Baby Care introduces FDA-cleared BabySat for enhanced infant monitoring. Garmin unveils new 'Lily' smartwatches focused on women's wellness. Vivoo unveils new at-home UTI test at CES. ReproTech introduces Cryo-Logix to streamline cryostorage for IVF clinics. Gynesonics, Inc. non-invasive uterine fibroid treatment gains official recognition with establishment of new CPT code. Contraline, Inc. first-in-human clinical trial shows promise for novel male contraceptive. Bayer announces positive Phase III results for non-hormonal treatment for menopause-related vasomotor symptoms.